Literature DB >> 25880698

Resting cortisol level, self-concept, and putative familial environment in adolescents at ultra high-risk for psychotic disorders.

Emily E Carol1, Vijay A Mittal2.   

Abstract

A growing body of evidence suggests that resting cortisol levels are elevated in patients with schizophrenia and closely tied to symptom severity. However, there is limited research on the biological stress system during the ultra high-risk (UHR) period immediately preceding the onset of psychosis, and cortisol has not been examined in relation to individual characteristics such as self-concept or potential stressors such as putative familial environment in this critical population. In the present study, salivary cortisol samples were collected on 37 UHR and 42 matched control adolescents, and these individuals were assessed with clinical interviews as well as a measure of self-concept. For a subsection of the sample (23 UHR and 20 control adolescents), a participating relative/caretaker was also assessed with an expressed emotion interview designed to gauge psychosocial environment. Consistent with previous studies, UHR participants exhibited elevated resting cortisol levels when compared with controls. In addition, UHR adolescents exhibited increased negative self-concept and their relatives/caretakers endorsed significantly fewer initial positive statements about the participant. Interestingly, a strong trend in the UHR group suggests that higher cortisol levels are associated with higher rates of critical statements from relatives/caretakers. Furthermore, elevated cortisol levels in the participants were associated with increased negative self-concept as well as fewer initial positive comments from relatives/caretakers. Results suggest that hypothalamic-pituitary-adrenal axis (HPA) dysfunction is closely associated with both individual and environmental-level characteristics. Taken together, these findings support a neural diathesis-stress model of psychosis and future studies, designed to examine causal relationships, stand to inform both our understanding of pathogenic processes in the high-risk period as well as early intervention efforts. Published by Elsevier Ltd.

Entities:  

Keywords:  Cortisol; Expressed emotion; HPA axis; High-risk; Prodrome; Schizophrenia

Mesh:

Substances:

Year:  2015        PMID: 25880698      PMCID: PMC4437835          DOI: 10.1016/j.psyneuen.2015.03.018

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  59 in total

1.  A cognitive model of the positive symptoms of psychosis.

Authors:  P A Garety; E Kuipers; D Fowler; D Freeman; P E Bebbington
Journal:  Psychol Med       Date:  2001-02       Impact factor: 7.723

2.  Inter-rater reliability of the SCID alcohol and substance use disorders section among adolescents.

Authors:  C S Martin; N K Pollock; O G Bukstein; K G Lynch
Journal:  Drug Alcohol Depend       Date:  2000-05-01       Impact factor: 4.492

3.  The development of multiple domains of child and adolescent self-concept: a cohort sequential longitudinal design.

Authors:  D A Cole; S E Maxwell; J M Martin; L G Peeke; A D Seroczynski; J M Tram; K B Hoffman; M D Ruiz; F Jacquez; T Maschman
Journal:  Child Dev       Date:  2001 Nov-Dec

Review 4.  Schizophrenia: genes and environment.

Authors:  M Tsuang
Journal:  Biol Psychiatry       Date:  2000-02-01       Impact factor: 13.382

Review 5.  Symptom assessment in schizophrenic prodromal states.

Authors:  T J Miller; T H McGlashan; S W Woods; K Stein; N Driesen; C M Corcoran; R Hoffman; L Davidson
Journal:  Psychiatr Q       Date:  1999

6.  Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia.

Authors:  D J Walder; E F Walker; R J Lewine
Journal:  Biol Psychiatry       Date:  2000-12-15       Impact factor: 13.382

7.  Expressed emotion in relatives of first-episode and chronic patients with schizophrenia and major depressive disorder-a comparison.

Authors:  Silke Bachmann; Christina Bottmer; Sarah Jacob; Klaus Thomas Kronmüller; Matthias Backenstrass; Christoph Mundt; Babette Renneberg; Peter Fiedler; Johannes Schröder
Journal:  Psychiatry Res       Date:  2002-11-15       Impact factor: 3.222

Review 8.  Possible role of cortisol and dehydroepiandrosterone in human development and psychopathology.

Authors:  I M Goodyer; R J Park; C M Netherton; J Herbert
Journal:  Br J Psychiatry       Date:  2001-09       Impact factor: 9.319

9.  Family-focused treatment of bipolar disorder: 1-year effects of a psychoeducational program in conjunction with pharmacotherapy.

Authors:  D J Miklowitz; T L Simoneau; E L George; J A Richards; A Kalbag; N Sachs-Ericsson; R Suddath
Journal:  Biol Psychiatry       Date:  2000-09-15       Impact factor: 13.382

10.  Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress.

Authors:  K H Nuechterlein; M E Dawson; M Gitlin; J Ventura; M J Goldstein; K S Snyder; C M Yee; J Mintz
Journal:  Schizophr Bull       Date:  1992       Impact factor: 9.306

View more
  12 in total

1.  Hippocampal Subregions Across the Psychosis Spectrum.

Authors:  Teresa Vargas; Derek J Dean; Kenneth Juston Osborne; Tina Gupta; Ivanka Ristanovic; Sekine Ozturk; Jessica Turner; Theo G M van Erp; Vijay Anand Mittal
Journal:  Schizophr Bull       Date:  2018-08-20       Impact factor: 9.306

2.  The relationship between cannabis use and cortisol levels in youth at ultra high-risk for psychosis.

Authors:  Emily E Carol; Robert L Spencer; Vijay A Mittal
Journal:  Psychoneuroendocrinology       Date:  2017-05-30       Impact factor: 4.905

3.  Lack of Diagnostic Pluripotentiality in Patients at Clinical High Risk for Psychosis: Specificity of Comorbidity Persistence and Search for Pluripotential Subgroups.

Authors:  Scott W Woods; Albert R Powers; Jerome H Taylor; Charlie A Davidson; Jason K Johannesen; Jean Addington; Diana O Perkins; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Thomas H McGlashan
Journal:  Schizophr Bull       Date:  2018-02-15       Impact factor: 9.306

4.  Core beliefs in healthy youth and youth at ultra high-risk for psychosis: Dimensionality and links to depression, anxiety, and attenuated psychotic symptoms.

Authors:  Henry R Cowan; Dan P McAdams; Vijay A Mittal
Journal:  Dev Psychopathol       Date:  2018-03-06

5.  Clues from caregiver emotional language usage highlight the link between putative social environment and the psychosis-risk syndrome.

Authors:  Tina Gupta; William S Horton; Claudia M Haase; Emily E Carol; Vijay A Mittal
Journal:  Schizophr Res       Date:  2022-04-07       Impact factor: 4.662

6.  Sex differences in morning cortisol in youth at ultra-high-risk for psychosis.

Authors:  Emily E Carol; Robert L Spencer; Vijay A Mittal
Journal:  Psychoneuroendocrinology       Date:  2016-06-21       Impact factor: 4.905

7.  Erythrocyte glutathione levels as long-term predictor of transition to psychosis.

Authors:  S Lavoie; M Berger; M Schlögelhofer; M R Schäfer; S Rice; S-W Kim; J Hesse; P D McGorry; S Smesny; G P Amminger
Journal:  Transl Psychiatry       Date:  2017-03-21       Impact factor: 6.222

8.  A comparative study of psychotic and affective symptoms in Rwandan and Kenyan students.

Authors:  A Owoso; S Jansen; D M Ndetei; A Musau; V N Mutiso; C Mudenge; A Ngirababyeyi; A Gasovya; D Mamah
Journal:  Epidemiol Psychiatr Sci       Date:  2017-01-26       Impact factor: 6.892

9.  Incorporating cortisol into the NAPLS2 individualized risk calculator for prediction of psychosis.

Authors:  Michelle A Worthington; Elaine F Walker; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Barbara A Cornblatt; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Scott W Woods; Tyrone D Cannon
Journal:  Schizophr Res       Date:  2020-10-09       Impact factor: 4.939

Review 10.  Narrative identity in the psychosis spectrum: A systematic review and developmental model.

Authors:  Henry R Cowan; Vijay A Mittal; Dan P McAdams
Journal:  Clin Psychol Rev       Date:  2021-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.